Compare CVS Health Corp (CVS) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs abrdn Physical Palladium Shares ETF — how do they compare? CVS Health Corp trades at $93.65 (market cap $122.36B), while abrdn Physical Palladium Shares ETF trades at $24.95. The key difference: CVS Health Corp pays a 2.78% dividend while abrdn Physical Palladium Shares ETF pays none, and CVS Health Corp is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| CVS | PALL | |
|---|---|---|
Market Cap | $122.36B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $110.60 | $37.18 |
52-Week Low | $65.51 | $19.96 |
Enterprise Value | $184.71B | — |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
PALL trades at $25.05, up 0.64% with bullish technical signals from moving averages. The stock recently underwent a 1:5 split on May 18, 2026. Technical indicators show mixed signals with RSI suggesting mild overbought conditions while ADX indicates strong trend strength. Support and resistance levels cluster around $25-$26, creating a key price zone.
PALL presents a contrarian opportunity as palladium prices remain 47% below January 2026 highs. Supply risks and industrial demand support long-term fundamentals, though the ETF faces commodity price volatility and Federal Reserve policy uncertainty as near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
